Ernesto Guccione, PhD
img_Ernesto Guccione
PROFESSOR | Oncological Sciences
PROFESSOR | Pharmacological Sciences
PROFESSOR | Immunology & Immunotherapy
Research Topics
Cancer, Developmental Biology, Epigenetics, Post-Transcriptional Processing
Multi-Disciplinary Training Area
Cancer Biology [CAB], Development Regeneration and Stem Cells [DRS]
Post-Transcriptional Processing, Epigenetics, Developmental Biology, Cancer
The Guccione lab has a long-standing interest in understanding basic mechanisms of transcriptional and post-transcriptional regulation in order to identify therapeutic opportunities in oncology. Currently, we are interested in the function in development and disease of Protein MethylTrasnferases (PMTs) and in modulation of Alternative Splicing using Antisense Oligonucleotide (AON)-based approaches. We use biochemistry, mouse models and next generation sequencing techniques to understand the molecular mechanisms of action of candidate PMTs or specific isoforms. The range of techniques and approaches used in the lab has allowed us to characterize the mechanism of action of specific PMTs (e.g. PRMT5 and PRMT6) or oncogenic isoforms (e.g. MDM4l/s), which are now of great interest for their clinical applications.

MS, University of Bologna

PhD, International School for Advanced Studies (SISSA)/International Center for Genetic Engineering Biotechnology (ICGEB)

Post Doc, European Institute of Oncology

Publications

Selected Publications

E7386 Enhances Lenvatinib’s Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma. Agavni Mesropian, Albert Gris-Oliver, Ugne Balaseviciute, Alka A. Potdar, Takayuki Kimura, Jialing Shen, Martí Torres-Marcén, Jordi Abril-Fornaguera, Marta Piqué-Gili, David Camell-Raventos, Judit Peix, Elisa Fernández-Martínez, Júlia Huguet-Pradell, Ana Hernández de Sande, Ieva Keraite, Roger Esteban-Fabró, Marina Bárcena-Varela, Katherine E. Lindblad, Amaia Lujambio, Ernesto Guccione, Swan Thung, Masafumi Ikeda, Masatoshi Kudo, Daniela Sia, Roser Pinyol, Josep M. Llovet. Clinical Cancer Research

Histone methyltransferase PRDM9 promotes survival of drug-tolerant persister cells in glioblastoma. George L. Joun, Emma G. Kempe, Brianna Chen, Jayden R. Sterling, Ramzi H. Abbassi, Dana Friess, Matthew Singleton, Chandra Choudhury, Oana C. Marian, W. Daniel du Preez, Ariadna Recasens, Teleri Clark, Tian Y. Du, Jason K.K. Low, Hani Kim, Pengyi Yang, Jasmine Khor, Monira Hoque, Dinesh C. Indurthi, Mani Kuchibhotla, Ranjith Palanisamy, William T. Jorgensen, Andrew P. Montgomery, Jennifer R. Baker, Sarah L. Higginbottom, Eva Tomaskovic-Crook, Jeremy M. Crook, Lipin Loo, Bryan W. Day, G. Gregory Neely, Ernesto Guccione, Terrance G. Johns, Michael Kassiou, Yuchen Feng, Lachlan Harris, Anthony S. Don, Lenka Munoz. Nature Communications

Maternal PRDM10 activates essential genes for oocyte-to-embryo transition. Michelle K.Y. Seah, Brenda Y. Han, Yan Huang, Louise J.H. Rasmussen, Andrina J. Stäubli, Judith Bello-Rodríguez, Andrew Chi Ho Chan, Maxime Gasnier, Heike Wollmann, Ernesto Guccione, Daniel M. Messerschmidt. Nature Communications

View All Publications

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Below are financial relationships with industry reported by Dr. Guccione during 2025 and/or 2026. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Board Service

  • Prometeo Therapeutics

Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership

  • Hyris
  • IFOM
  • Prometeo Therapeutics

Editorial Services

  • Epigenomes

Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)

  • Prometeo Therapeutics

Founder/Co-Founder/Partner

  • Prometeo Therapeutics

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.